AU2018286754A1 - Treatment of inflammatory diseases with inhibitors of C5A activity - Google Patents

Treatment of inflammatory diseases with inhibitors of C5A activity Download PDF

Info

Publication number
AU2018286754A1
AU2018286754A1 AU2018286754A AU2018286754A AU2018286754A1 AU 2018286754 A1 AU2018286754 A1 AU 2018286754A1 AU 2018286754 A AU2018286754 A AU 2018286754A AU 2018286754 A AU2018286754 A AU 2018286754A AU 2018286754 A1 AU2018286754 A1 AU 2018286754A1
Authority
AU
Australia
Prior art keywords
antibody
antigen
binding
compound
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018286754A
Other languages
English (en)
Inventor
Renfeng Guo
Niels R. Riedemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InflaRx GmbH
Original Assignee
InflaRx GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InflaRx GmbH filed Critical InflaRx GmbH
Publication of AU2018286754A1 publication Critical patent/AU2018286754A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AU2018286754A 2017-06-23 2018-06-13 Treatment of inflammatory diseases with inhibitors of C5A activity Abandoned AU2018286754A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17177657 2017-06-23
EP17177657.8 2017-06-23
EP17189938.8 2017-09-07
EP17189938 2017-09-07
PCT/EP2018/065676 WO2018234118A1 (en) 2017-06-23 2018-06-13 Treatment of inflammatory diseases with inhibitors of c5a activity

Publications (1)

Publication Number Publication Date
AU2018286754A1 true AU2018286754A1 (en) 2019-12-19

Family

ID=62636193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018286754A Abandoned AU2018286754A1 (en) 2017-06-23 2018-06-13 Treatment of inflammatory diseases with inhibitors of C5A activity

Country Status (10)

Country Link
EP (1) EP3642230A1 (cg-RX-API-DMAC7.html)
JP (1) JP7502865B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200020727A (cg-RX-API-DMAC7.html)
CN (1) CN111201241A (cg-RX-API-DMAC7.html)
AU (1) AU2018286754A1 (cg-RX-API-DMAC7.html)
CA (1) CA3066689C (cg-RX-API-DMAC7.html)
IL (1) IL271074A (cg-RX-API-DMAC7.html)
SG (1) SG11201912882QA (cg-RX-API-DMAC7.html)
TW (1) TWI786132B (cg-RX-API-DMAC7.html)
WO (1) WO2018234118A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102667023B1 (ko) 2016-06-14 2024-05-21 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
CN113574072B (zh) * 2019-03-14 2023-12-12 莫佛塞斯公司 靶向C5aR的抗体
TWI869528B (zh) * 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
EP4126222A1 (en) * 2020-03-27 2023-02-08 InflaRx GmbH Inhibitors of c5a for the treatment of corona virus infection
JP7674399B2 (ja) * 2020-06-24 2025-05-09 スタイドソン・（ベイジン）・バイオファーマシューティカルズ・カンパニー・リミテッド Ｃ５ａを特異的に認識する抗体およびその使用
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
EP2578683B9 (en) 2004-02-12 2015-04-15 Archemix LLC Aptamer therapeutics useful in the treatment of complement-related disorders
CA2560902A1 (en) * 2004-03-26 2005-10-06 Promics Pty Limited Treatment of neurological conditions using complement c5a receptor modulators
CA2658352A1 (en) 2006-07-21 2008-01-24 Promics Pty Ltd Treatment for intimal hyperplasia and related conditions
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
SG172338A1 (en) 2008-12-22 2011-07-28 Chemocentryx Inc C5ar antagonists
GB0905790D0 (en) * 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
HRP20171176T1 (hr) * 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
EP3312281A3 (en) * 2013-03-14 2018-06-27 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
CN105392803B (zh) * 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途
JP6718379B2 (ja) * 2014-03-20 2020-07-08 インフラルクス ゲーエムベーハー ウイルス性肺炎治療のためのＣ５ａの阻害剤
WO2016044419A1 (en) 2014-09-16 2016-03-24 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
ES2719876T3 (es) 2014-10-15 2019-07-16 Alexion Pharma Inc Métodos para replicar un cultivo celular de producción de eculizumab a gran escala
FR3030515B1 (fr) * 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
JP2018520139A (ja) 2015-06-26 2018-07-26 アレクシオン ファーマシューティカルズ， インコーポレイテッド エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法
JP7121722B2 (ja) 2016-04-04 2022-08-18 ケモセントリックス，インコーポレイティド 可溶性Ｃ５ａＲアンタゴニスト
ES2893769T3 (es) * 2017-04-03 2022-02-10 Inflarx Gmbh Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a

Also Published As

Publication number Publication date
CA3066689C (en) 2024-01-16
JP2020524696A (ja) 2020-08-20
TW201904611A (zh) 2019-02-01
TWI786132B (zh) 2022-12-11
IL271074A (en) 2020-01-30
CA3066689A1 (en) 2018-12-27
WO2018234118A1 (en) 2018-12-27
CN111201241A (zh) 2020-05-26
KR20200020727A (ko) 2020-02-26
EP3642230A1 (en) 2020-04-29
JP7502865B2 (ja) 2024-06-19
SG11201912882QA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US11890349B2 (en) Treatment of inflammatory diseases with inhibitors of C5A activity
US11273225B2 (en) Treatment of inflammatory diseases with inhibitors of C5a activity
CA3066689C (en) Treatment of inflammatory diseases with inhibitors of c5a activity
KR102513989B1 (ko) 간 질환을 치료하거나 예방하는 방법
US20230158060A1 (en) Inhibitors of C5a for the Treatment of Corona Virus Infection
HK40070841A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
HK40101423A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
EA043076B1 (ru) Лечение воспалительных заболеваний с помощью ингибиторов активности c5a
US20240343787A1 (en) Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
HK40000612B (en) Treatment of inflammatory diseases with inhibitors of c5a activity
EA049533B1 (ru) ИНГИБИТОРЫ С5а ДЛЯ ЛЕЧЕНИЯ КОРОНАВИРУСНОЙ ИНФЕКЦИИ

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted